Extended release formulations of anticonvulsant medications clinical pharmacokinetics and therapeutic advantages

CNS Drugs

Volumn 14, Issue 3, 2000, Pages 203-212

  Collins, R J ^a   Garnett, W R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; DEPAKOTE SPRINKLE; GABAPENTIN; LAMOTRIGINE; NEUROTOL SLOW; OXCARBAZEPINE; PHENOBARBITAL; TERIL CR; TIAGABINE; TOPIRAMATE; TRIMONIL RETARD; VALPROATE SEMISODIUM; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MONITORING; DRUG SAFETY; EPILEPSY; HUMAN; LONG TERM CARE; META ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SUSTAINED RELEASE FORMULATION;

EID: 0033829095     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200014030-00003     Document Type: Review

References (27)

1. Descriptive epidemiology of epilepsy: Contributions of population-based studies from Rochester, Minnesota
2. Epilepsy
3. How often is medication taken as prescribed? A novel assessment technique
4. Pharmacokinetic evaluation of sustained release formulations of antiepileptic drugs
5. General principles: Formulations and route of administration
6. Clinical pharmacokinetics of new antiepileptic drugs
7. Carbamazepine: Absorption, distribution, and excretion
8. Administration of carbatrol® (carbamazepine extended-release capsules) via feeding tubes [abstract 2.055]
9. Occlusion of feeding gastrostomy tubes with extended-release carbamazepine capsules
10. Pharmacokinetic evaluation of twice-daily extended-release carbamazepine and four-times-daily immediate-release carbamazepine in patients with epilepsy
11. Six-month evaluation of Carbatrol (extended-release carbamazepine) in complex partial seizures
12. Elementary osmotic pump
13. Peroral solids, capsules, tablets, and controlled-release dosage forms
14. Comparative bioavailability and steady state fluctuations of Tegretol commercial and carbamazepine OROS tablets in adult and pediatric epileptic patients
15. 15N-labelled drug to healthy volunteers
16. Double-blind crossover comparison of Tegretol-XR and Tegretol in patients with epilepsy
17. Controlled, multidose, pharmacokinetic evaluation of two extended-release carbamazepine formulations (Carbatrol and Tegretol-XR)
18. Pharmacokinetic comparison of two carbamazepine slow-release formulations
19. Diurnal variation in carbamazepine and carbamazepine 10, 11-expoxide in plasma and saliva in children with epilepsy: A comparison between conventional and slow-release formulations
20. Reduction of dosing frequency of carbamazepine with a slow release preparation
21. Multiple-dose pharmacokinetic study with slow-release carbamazepine preparation
22. A double blind comparison of conventional and controlled-release carbamazepine in healthy subjects
23. Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepine
24. Criteria to assess in vivo performance and bioequivalence of generic controlled-release formulations of carbamazepine
25. Pharmacokinetic evaluation of novel sustained-release dosage forms of valproic acid in humans
26. Epilim® Chrono: A multidose, crossover comparison of two formulations of valproate in healthy volunteers
27. Comparison of sprinkle versus syrup formulations of valproate for bioavailability, tolerance, and preference